RESEARCH TRIANGLE PARK, N.C., May 5, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that the underwriters of its recently completed initial public offering (IPO) have partially exercised their option to purchase shares of common stock from Tranzyme to cover over-allotments. The sale of the additional shares closed on May 4, 2011.
